-+ 0.00%
-+ 0.00%
-+ 0.00%

Clinuvel flags superior release profile in VLRX-L injectable peptide platform study

PUBT·08/12/2026 02:24:20
Listen to the news
Clinuvel flags superior release profile in VLRX-L injectable peptide platform study
  • Clinuvel updated on VLRX-L, a controlled-release liquid injectable peptide platform, following new preclinical data.
  • One of four candidate formulations showed a stronger release profile, lower peak plasma levels, and drug presence across the target window.
  • Work now shifts to refining the lead formulation at its Singapore RD&I center, with another preclinical study slated for early Q1 2027.
  • Manufacturing scale-up is being scoped, with initial platform focus on melanocortin peptides for flexible, individualized dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.